Search PubMed⌕ Search

Biomedical subjects

L EIDUS

Publications and source records attributed to L EIDUS.

At least 19 recordsLinked to original sources

SPECIFICITY OF THE ISONIAZID DROP TEST FOR CONTROL OF DOMICILIARY TREATMENT OF TUBERCULOSIS.

A method for determining N-acetyl isoniazid in urine was found to be specific in a double-blind experiment on 1673 urine specimens of which 328 were positive and 1345 were negative. The urine specimens were obtained from patients in a sanatorium ((a) Tuberculosis Division, (b) Mental Health Division) and a general hospital. The patients in the Tuberculosis Division were receiving isoniazid and other antituberculosis drugs alone or in combination. The patients in the Mental Health Division and in the general hospital were receiving a wide variety of other drugs. After a single dose of 300 mg. of isoniazid, N-acetyl isoniazid could be detected in urines of 36 patients for at least 12 hours. In three 24-hour urine specimens trace amounts could still be demonstrated.This test provides evidence that isoniazid is being ingested by home-treated tuberculous patients, and it can be performed by a doctor or nurse during routine visits to the home or clinic.

Antitubercular Agents↗

PSEUDOGOUT.

Explore the source record for details and available documents.

Adrenal Cortex Hormones↗

SPECTATOR SEX.

Explore the source record for details and available documents.

Humans↗

A CLINICAL STUDY OF ISONIAZID INACTIVATION.

The rate of inactivation of isoniazid (INH) in a host organism varies widely, probably because of genetic factors. A simple chemical test was used to determine INH levels in 24 tuberculous patients three and six hours after oral administration of the drug. Results are expressed in terms of half-life values of free INH in the body. Seven of the 24 patients inactivated INH rapidly (half-life average: 64 minutes); the remaining 17 metabolized INH at a slower rate (half-life average: 186 minutes). The range of individual half-life values was 30 to 305 minutes. A provisional half-life limit of 110 minutes was used to define "fast inactivators"; 110-160 minutes, "moderate inactivators"; and over 160 minutes, "slow inactivators". Although INH inactivation may not be directly related to therapeutic failure, the security margin of the treatment may be diminished in those patients who inactivate INH rapidly.

Administration, Oral↗